Stroke thrombolysis in england: An age stratified analysis of practice and outcome

Age and Ageing

Volumn 42, Issue 2, 2013, Pages 240-245

  Bray, Benjamin D ^a   Campbell, James ^b   Hoffman, Alex ^b   Tyrrell, Pippa J ^c   Wolfe, Charles D A ^a,d   Rudd, Anthony G ^e  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b ROYAL COLLEGE OF PHYSICIANS   (United Kingdom)

^c SALFORD ROYAL NHS FOUNDATION TRUST   (United Kingdom)

^d GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^e ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Age; Mortality; Older people; Stroke; Thrombolysis

Indexed keywords

RECOMBINANT PLASMINOGEN ACTIVATOR;

ADULT; AGE DISTRIBUTION; AGED; ANGIONEUROTIC EDEMA; ARTICLE; BRAIN HEMORRHAGE; BRAIN HYPOXIA; BRAIN INFARCTION; BRAIN ISCHEMIA; CLINICAL PRACTICE; CONSCIOUSNESS DISORDER; FEMALE; FIBRINOLYTIC THERAPY; HUMAN; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; UNITED KINGDOM;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CHI-SQUARE DISTRIBUTION; ENGLAND; FEMALE; FIBRINOLYTIC AGENTS; HEALTH SERVICES ACCESSIBILITY; HUMANS; LOGISTIC MODELS; MALE; MEDICAL AUDIT; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PATIENT SELECTION; PHYSICIAN'S PRACTICE PATTERNS; QUALITY IMPROVEMENT; RECOMBINANT PROTEINS; RISK FACTORS; STROKE; THROMBOLYTIC THERAPY; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84874510640     PISSN: 00020729     EISSN: 14682834     Source Type: Journal    
DOI: 10.1093/ageing/afs167     Document Type: Article

References (23)

1. Intercollegiate Stroke Working Party. National Clinical Guidelines for Stroke. http://www.rcplondon.ac.uk/resources/stroke-guidelines. (2 April 2012, date last accessed).
2. Asdaghi N, Butcher KS, Hill MD. Risks and benefits of thrombolysis in the elderly. Int J Stroke 2012; 7: 142-9.
3. Bonita R. Epidemiology of stroke. Lancet 1992; 339: 342-4.
4. Rothwell PM, Coull AJ, Giles MF et al.. Change in stroke incidence, mortality, case-fatality, severity and risk factors in Oxfordshire, UK from 1981 to 2004 (Oxford Vascular Study). Lancet 2004; 363: 1925-33.
5. Truelsen T, Prescott E, Gronbaek M, Schnohr P, Boysen G. Trends in stroke incidence. The Copenhagen City Heart Study. Stroke 1997; 28: 1903-7.
6. The IST-3 Collaborative group. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute iscaemic stroke. Lancet 2012; 279: 2352-63.
7. Meseguer E, Labreuche J, Olivot JM et al.. Determinants of outcome and safety of intravenous rt-PA therapy in the very old: a clinical registry study and systematic review. Age Ageing 2008; 37: 107-111.
8. Engelter ST, Bonati LH, Lyrer PA. Intravenous thrombolysis in stroke patients of >or = 80 versus <80 years of age-a systematic review across cohort studies. Age Ageing 2006; 35: 572-80.
9. Mishra NK, Ahmed N, Andersen G et al. Thrombolysis in very elderly people: controlled comparison of SITS International Stroke Thrombolysis Registry and Virtual International Stroke Trials Archive. BMJ 2011; 341: c6046.
10. Sylaja PN, Cote R, Buchan AM, Hill MD. Thrombolysis in patients older than 80 years with acute ischaemic stroke: Canadian alteplase for stroke effectiveness study. J Neurol Neurosurg Psychiatry 2006; 77: 826-9.
11. Ford GA, Ahmed N, Azvedo E et al.. Intravenous alteplase for stroke in those older than 80 years old. Stroke 2010; 41: 2568-2574.
12. The National Institute of Neurological Disorders and Stroke rt-PA Study Group. Tissue plasminogen activator for acute ischaemic stroke. NEJM 1995; 333: 1581-8.
13. Wardlaw JW, Murray V, Berge E, Del Zoppo GJ. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev 2009; 4: CD000213.
14. Actilyse. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Actilyse/human_referral_000069. jsp&mid=WC0b01ac0580024e9a. (3 April 2012, date last accessed).
15. Medical Research Information Service. http://www.ic.nhs.uk/services/medical-research-information-service. (2 April 2012, date last accessed).
16. Stroke Improvement National Audit Programme. http://www.rcplondon.ac.uk/resources/stroke-improvement-nationalaudit-programme-sinap. (19 March 2012, date last accessed).
17. Bamford J, Sandercock P, Dennis M, Burn J, Warlow C. Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet 1991; 337: 1521-26.
18. Newcombe RJ. Two-sided confidence intervals for the single proportion: comparison of seven methods. Statist Med 1998; 17: 857-72.
19. Wahlgren N, Ahmed N, Davalos A et al.. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 2007; 369: 275-282 (Erratum, Lancet 2007;369:826).
20. Hill MD, Buchan AM; for the Canadian Alteplase for Stroke Effectiveness Study (CASES) Investigators. Thrombolysis for acute ischaemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study. CMAJ 2005; 172: 1307-12.
21. Hill MD, Lye T, Moss H et al.. Hemi-orolingual angioedema and ACE inhibition after alteplase treatment of stroke. Neurology 2003; 60: 1525-7.
22. Saposnik G, Kapral MK, Coutts SB et al.. Do all age groups benefit from organized inpatient stroke care? Stroke 2009; 40: 3321-7.
23. Kammersgaard LP, Jorgensen HS, Reith J, Nakayama H, Pedersen PM, Olsen TS. Short- and long-term prognosis for very old stroke patients. The Copenhagen Stroke Study. Age Ageing 2004; 33: 149-54.